Your Trusted Partner For Clinical Research and Pharmacovigilance

Clinical Trial Regulatory Framework in India: Complete Guide (NDCTR & CDSCO)

Introduction

Companies planning to conduct clinical trials in India often have queries regarding the clinical trial approval process in India and the overall regulatory pathway. Before outsourcing clinical trials to Contract Research Organizations in India, it is essential to understand the clinical trial regulatory framework in India and how different regulatory components interact.

India has evolved into a structured and globally aligned clinical research destination, supported by clearly defined clinical research regulations in India. These regulations ensure that trials are conducted ethically, efficiently, and in compliance with international standards.

To simplify this complex landscape, this guide answers the most common industry questions while explaining NDCTR 2019 India, CDSCO clinical trial approval, and key compliance requirements.

Clinical Trial regulatory framework in India

1. What is the Clinical Trial Regulatory Framework in India?

The clinical trial regulatory framework in India is governed by the New Drugs and Clinical Trials Rules (NDCTR), 2019 under CDSCO.

The framework defines how clinical trials should be conducted, reviewed, approved, and monitored in India. It is aligned with global standards such as ICH-GCP, ensuring that data generated from clinical trials in India is accepted worldwide.

This regulatory system covers multiple categories, including drugs, biologics, vaccines, and medical devices, as well as different trial types such as global clinical trials, investigational new drugs (INDs), and Bioavailability (BA)/ Bioequivalence (BE) studies.

Organizations providing consultations for clinical trial regulatory framework in India play a key role in helping sponsors navigate this framework efficiently.

2. What is New Drugs and Clinical Trials Regulations (NDCTR) 2019 and Why is it Important?

NDCTR 2019 is the principal regulatory framework governing clinical trials in India.

The introduction of NDCTR 2019 India marked a major shift toward transparency, faster approvals, and stronger participant protection.

It provides:

By streamlining processes, NDCTR has significantly improved the clinical trial approval process in India, making it more predictable and globally competitive.

3. Who Regulates Clinical Trials in India?

Clinical trials in India are regulated by CDSCO, with approvals granted by the DCGI.

The regulatory ecosystem includes multiple authorities working together:

The DCGI oversees the approval of new drugs and clinical trials, and sets standards for the manufacture, import, and sale of drugs and cosmetics. The DCGI acts as the central licensing authority for specific, high-risk categories.

While CDSCO is responsible for clinical trial approval in India, Ethics Committees ensure ethical conduct, and CTRI ensures transparency through mandatory trial registration.

The Indian Council of Medical Research (ICMR) facilitates clinical research in India by acting as the apex body for planning, coordinating, and funding biomedical research. ICMR plays a critical role in setting ethical guidelines, registering clinical trials, and developing research infrastructure for clinical, translational, and public health studies.

This multi-layered system ensures that clinical trials in India guidelines are strictly followed.

4. What is the Clinical Trial Approval Process in India?

The clinical trial approval process in India involves regulatory, ethical, and registration steps before study initiation.

The process typically includes:

Each step plays a critical role in ensuring compliance with clinical research regulations in India.

A well-prepared submission significantly reduces delays, which is why sponsors often partner with a CRO for clinical trials in India.

5. What are the Key Components of Regulatory Compliance?

Regulatory compliance in India is comprehensive and designed to ensure participant safety and data integrity.

It includes approval from CDSCO, Ethics Committee clearance, and CTRI registration, along with strict adherence to safety reporting timelines and ongoing regulatory submissions.

Sponsors must also ensure:

These requirements collectively strengthen the credibility of clinical trials in India.

6. What is the Role of Ethics Committee Approval in India?

Ethics Committee approval in India is mandatory before initiating any clinical trial.

Ethics Committees (ECs), also referred to as Institutional Ethics Committees (IECs), are responsible for reviewing the scientific and ethical aspects of a study.

They evaluate:

The importance of ethics committee approval in India clinical trials cannot be overstated, as it ensures that participant rights and safety remain central to the research process.

7. What is CTRI Registration and Why is it Important?

CTRI registration in India is mandatory before enrolling the first patient in a clinical trial.

The Clinical Trials Registry of India (CTRI) improves transparency and accountability by making trial details publicly accessible.

It helps:

Proper CTRI registration India is a critical step in the clinical trial lifecycle and a key compliance requirement.

8. Is there a Central Institutional Review Board (IRB) in India?

In India, there are Institutional Ethics Committee/ Independent Ethics Committee (IEC). The Ethics Committees (EC) are registered with the CDSCO. Ethics committee approval is mandatory for all clinical trials in India. They also provide oversight monitoring for clinical trials. ECs evaluate the risk–benefit ratio, informed consent process, participant safety measures, and investigator credentials before granting approval. Their jurisdiction covers trial sites within a 50-kilometer radius. Ethics committee oversight ensures trials are conducted ethically and in compliance with national and international standards. In India, Institutional Ethics Committees (IECs) monitor clinical trials and biomedical research by reviewing ongoing studies, protocol violations, and serious adverse events (SAEs).

9. What are the Safety Reporting Requirements in India?

Safety reporting in India requires timely reporting of all serious adverse events (SAEs).

India has stricter safety reporting requirements compared to many countries. Investigators must report all SAEs to CDSCO, ECs, Sponsors & Head of Institutes  (HOI) within 24 hours, and final or next version reports must be submitted within 14 days.

Reporting timelines in other countries for life-threatening and death need is 7 days, whereas the SAEs have a timeline reporting of 15 days.

Unlike other regions, India requires reporting of all SAEs—not just SUSARs—which strengthens patient safety monitoring.

These safety reporting requirements in India clinical trials ensure continuous oversight throughout the study.

10. How to Get Clinical Trial Approval in India?

To get clinical trial approval in India, sponsors must follow a structured regulatory and ethical process.

This includes:

Understanding how to get clinical trial approval in India requires both regulatory knowledge and operational expertise.

This is where experienced clinical trial regulatory consulting in India becomes valuable.

11. How does India Ensure International Compliance in Clinical Research?

India follows international standards like the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) for clinical trials. This helps ensure that clinical trials in India are conducted responsibly and that the data generated is reliable. As a result, clinical data generated from clinical trials conducted in India is accepted by regulatory authorities around the world. CROs in India need to be registered with CDSCO and be FDA/CDSCO compliant. The staff has prior experience interacting with global agencies and strong quality management systems (QMS). CROs like CLINEXEL are working with Sponsors from the United States and Europe, alongside collaborating with global CROs.

12. What are the Common Regulatory Challenges in India?

Despite improvements, challenges still exist in the regulatory process.

These include:

Addressing these challenges requires a deep understanding of clinical trials in India guidelines and local clinical practices.

Working with experienced Clinical Research Organizations in India helps mitigate these risks and ensures smoother approvals.

13. How CROs such as CLINEXEL Support Clinical Trials in India

CROs like CLINEXEL play a crucial role in simplifying regulatory and operational complexities.

A reliable CRO for clinical trials in India provides:

Organizations offering CDSCO regulatory support in India ensure that sponsors meet all compliance requirements efficiently.

Conclusion

The clinical trial regulatory framework in India has evolved into a structured, transparent, and globally aligned system. With the implementation of NDCTR 2019 India, defined approval timelines, and strong ethical oversight, India has become an increasingly attractive destination for clinical research.

Understanding the clinical trial approval process in India, along with key components such as CDSCO clinical trial approval, CTRI registration India, and safety reporting requirements, is essential for successful trial execution.

As the regulatory landscape continues to mature, sponsors who leverage expert guidance and collaborate with experienced CROs will be better positioned to navigate complexities and accelerate clinical development in India.

Frequently Asked Questions (FAQs)

1. What is the clinical trial regulatory framework in India?

The framework is governed by NDCTR 2019 under CDSCO, defining how trials are approved and conducted.

2. What is NDCTR 2019?

NDCTR 2019 is the primary regulation for clinical trials in India, ensuring safety, transparency, and efficiency.

3. Who regulates clinical trials in India?

CDSCO and DCGI regulate clinical trials, supported by Ethics Committees and CTRI.

4. How to get clinical trial approval in India?

Sponsors must submit a CTA, obtain CDSCO and EC approvals, and complete CTRI registration.

5. What is CTRI registration?

CTRI registration is mandatory before patient enrollment and ensures trial transparency.

6. Why work with a CRO in India?

CROs provide regulatory expertise, faster approvals, and end-to-end clinical trial support.

 

Authors:

Guidelines for Clinical Trials in India by Dr. Deepa Arora- CEO- CLINEXEL
Dr. Deepa Arora- CEO- CLINEXEL ( https://www.linkedin.com/in/deepaarora2019/ )

Dr Deepa is a physician with 25+ years of industry experience in leadership positions with pharma in Clinical Development, Medical Research, and Drug Safety departments.

Dr. Deepa led an industry consortium for the implementation of additional risk minimization measures in Europe. Her experience includes the development and execution of clinical development strategy and conducting clinical trials for NCEs, biosimilars, vaccines, complex generics, and repurposed drugs.

Deepa has experience in interacting with various regulators- USFDA, EMA, MHRA, MEB, Health Canada, WHO, TGA for scientific advice, pre-IND meetings, end of phase meetings to discuss clinical development path, clinical trial designs, and post-marketing commitments, including PMS/ Phase IV studies and paediatric investigation plan (PIP).

Guidelines for Clinical Trials in India bu Dr. Mukesh Kumar
Dr. Mukesh Kumar– Chief Scientific Officer- CLINEXEL (https://www.linkedin.com/in/dr-mukesh-kumar-m-d-6223457/)

A Physician (MD) with over 25 years of deep expertise in clinical R&D, Dr Kumar’s career is a testament to innovation and excellence in clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. His contributions have driven global product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.

Dr. Kumar’s illustrious career includes clinical R&D leadership roles at global pharmaceutical giants (Sanofi and Daiichi Sankyo) and large Indian pharma companies (CIPLA, DRL, and LUPIN), where he supported early and late phase clinical trials of innovative products, including repurposed drugs via 505(b)(2) path, complex generics, and biosimilars.

He has played a key role in transforming the R&D business through clinical risk mitigation strategies and high-quality clinical trial executions. With a proven track record of significant contributions in clinical development of over 100 successful product registrations in the U.S. and Europe, he has redefined efficiencies in clinical strategies by implementing cost-effective, innovative clinical trials and pharmacology studies.

As CLINEXEL’s CSO, Dr. Kumar oversees clinical trial operations (Phases I-IV) and clinical program management. His value-added support is available for CLINEXEL-managed clinical trials in optimizing clinical strategies, global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics.